Biotechnology

Techseriesinsight > Blog > News > Biotechnology

December 24, 2024
Business Wire
Biotechnology

Anaergia to Supply Organic Waste to Energy Solution to PepsiCo in Colombia

Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced today that its Canadian subsidiary, Anaergia DB Inc., has entered into an integrated technology supply contract with PepsiCo Alimentos Z.F....

December 24, 2024
PRNewswire
Biotechnology

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I clinical trial of RAG-17,...

December 23, 2024
PRNewswire
Biotechnology

Aptamer developed by HKBU for treating rare bone disease ‘X-linked hypophosphatemia’ receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA

A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People’s Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People’s Hospital) has discovered...

December 23, 2024
Business Wire
Biotechnology

Ellipses Launches Pioneering Clinical Trial Programme in Middle East

Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the...

December 20, 2024
PRNewswire
Biotechnology

Rare Disease Consulting: Explore How to Address the Low Prevalence and High Outstanding Therapeutics Needs, and Stay Ahead by Understanding the Gaps in the Rare Diseases Market with DelveInsight

At DelveInsight, we take pride in being a leading provider of pharma competitive intelligence and consulting solutions, specializing in the rare diseases domain. With over 350 epidemiology-based market reports published,...

December 19, 2024
Business Wire
Biotechnology

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase IIb PADOVA study conducted by partner Roche investigating prasinezumab in 586 people with early-stage Parkinson’s disease, treated for a...

December 19, 2024
PRNewswire
Biotechnology

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced they have entered into a license agreement allowing...

December 18, 2024
PRNewswire
Biotechnology

Bridge to Life Acquires VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.

Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, has acquired the VitaSmart™ Hypothermic Oxygenated Machine Perfusion System from Medica S.p.A.. The agreement also includes...

December 18, 2024
PRNewswire
Biotechnology

Novo Nordisk Foundation grants €134.1 million to establish the Biotechnology Research Institute for the Green Transition (BRIGHT) in Denmark

Our daily lives are full of products and processes based on fossil materials, or created using fossil energy sources such as oil and gas. To make significant progress in...

December 18, 2024
Business Wire
Biotechnology

Sensorion Reports Data in the Audiogene Phase 1/2 Gene Therapy Clinical Trial

Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, announced today latest data updates confirming...